Advertisement

Gastric Cancer Worldwide Except Japan

  • Mimi C. Tan
  • Maya Balakrishnan
  • David Y. GrahamEmail author
Chapter

Abstract

Until recently, gastric cancer was the most common cause of cancer deaths. Despite the rapid fall in incidence, gastric cancer is still the fifth most common cancer and third leading cause of cancer-related mortality worldwide. The lifetime risk of gastric cancer to age 74 remains between 1 and 3% in most European countries and as high as 5–20% in some parts of Asia. The discovery of Helicobacter pylori as the cause of atrophic gastritis, the lesion that predisposes to gastric cancer, has resulted in increasing attempts to eliminate gastric cancer by eradicating H. pylori. Here we review the worldwide changes in gastric cancer incidence and the current lifetime risk.

Keywords

Gastric cancer Epidemiology Helicobacter pylori Epidemiology Risk factors 

Notes

Acknowledgments

Support: Dr. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center.

Disclosures: Dr. Graham is a consultant for RedHill Biopharma regarding novel H. pylori therapies and has received research support for culture of Helicobacter pylori and is the PI of an international study of the use of antimycobacterial therapy for Crohn’s disease. He is also a consultant for BioGaia in relation to probiotic therapy for H. pylori infection and for Takeda in relation to H. pylori therapies. Drs. Tan and Balakrishnan do not have any relevant disclosures.

References

  1. 1.
    Hoffman FL. The mortality from cancer throughout the world. Newark: Prudential Press; 1915.Google Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.CrossRefGoogle Scholar
  3. 3.
    Rielgel F. Carcinoma of the stomach. In: Stockton CG, editor. Diseases of the stomach in Nothnagel’s encyclopedia of practice of medicine. Nothnagel’s practice. Philadelphia: W.B. Saunders & Company; 1903. p. 644.Google Scholar
  4. 4.
    Williams WR. The increase of cancer, and its concomitants. In: Williams WR, editor. The natural history of cancer. New York: William Wood and Company; 1908. p. 55.Google Scholar
  5. 5.
    Haberlin H. Uber verbreitung und aetiologie des magenkrebses. Ueber neue diagnostische Humsmittel beim magenhkrebs. Arch F Klin, Med; Xlv. 1889.Google Scholar
  6. 6.
    Faber K. Chronic gastritis: its relation to achylia and ulcer. Lancet. 1927;2:902–7.Google Scholar
  7. 7.
    Faber K. Gastritis and its consequences. Paris: Oxford University Press; 1935.Google Scholar
  8. 8.
    Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol. 2010;45:1–8.CrossRefGoogle Scholar
  9. 9.
    Hurst AF. Schorstein lecture on the precursors of carcinoma of the stomach. Lancet. 1929;214:1023–8.CrossRefGoogle Scholar
  10. 10.
    Bockus HL. Carcinoma of the stomach. In: Bockus HL, editor. Gastroenterology, vol. 1. Philadelphia: W.B. Saunders Co.; 1963. p. 748.Google Scholar
  11. 11.
    von den Velden R. Ueber vorkommen und mandgel der freien salzsaure in magensaft bei gastrektasie. Deutsches Arch F Klin Med. 1879;23:369–99.Google Scholar
  12. 12.
    Comfort MW, Vanzant FR. Gastric acidity in carcinoma of the stomach. Am J Surg. 1934;26:447–56.CrossRefGoogle Scholar
  13. 13.
    Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med. 1951;36:1331–48.Google Scholar
  14. 14.
    Kikuchi S, Nakajima T, Kobayashi O, et al. Effect of age on the relationship between gastric cancer and Helicobacter pylori. Tokyo Research Group of Prevention for Gastric Cancer. Jpn J Cancer Res. 2000;91:774–9.CrossRefGoogle Scholar
  15. 15.
    Masci E, Viale E, Freschi M, et al. Precancerous gastric lesions and Helicobacter pylori. Hepatogastroenterology. 1996;43:854–8.PubMedGoogle Scholar
  16. 16.
    Urita Y, Hike K, Torii N, et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci. 2004;49:795–801.CrossRefGoogle Scholar
  17. 17.
    Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol. 2000;35(Suppl 12):90–7.PubMedGoogle Scholar
  18. 18.
    Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20:5191–204.CrossRefGoogle Scholar
  19. 19.
    Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut. 2005;54:735–8.CrossRefGoogle Scholar
  20. 20.
    Wang C, Weber A, Graham DY. Age, period, and cohort effects on gastric cancer mortality. Dig Dis Sci. 2015;60:514–23.CrossRefGoogle Scholar
  21. 21.
    Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60.CrossRefGoogle Scholar
  22. 22.
    Correa P, Cuello C, Duque E, et al. Gastric cancer in Colombia. III. Natural history of precursor lesions. J Natl Cancer Inst. 1976;57:1027–35.CrossRefGoogle Scholar
  23. 23.
    El-Zimaity HM, Ota H, Graham DY, et al. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer. 2002;94:1428–36.CrossRefGoogle Scholar
  24. 24.
    Graham DY, Kato M, Asaka M. Gastric endoscopy in the 21st century: appropriate use of an invasive procedure in the era of non-invasive testing. Dig Liver Dis. 2008;40:497–503.CrossRefGoogle Scholar
  25. 25.
    Schmidt PH, Lee JR, Joshi V, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest. 1999;79:639–46.PubMedGoogle Scholar
  26. 26.
    Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–31.CrossRefGoogle Scholar
  27. 27.
    Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017;19:e4.CrossRefGoogle Scholar
  28. 28.
    Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493–8.CrossRefGoogle Scholar
  29. 29.
    El-Zimaity HMT, Gutierrez O, Kim JG, et al. Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients. Am J Gastroenterol. 2001;96:666–72.CrossRefGoogle Scholar
  30. 30.
    Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150–8.CrossRefGoogle Scholar
  31. 31.
    Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56:631–6.CrossRefGoogle Scholar
  32. 32.
    Song H, Ekheden IG, Zheng Z, et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015;351:h3867.CrossRefGoogle Scholar
  33. 33.
    Li D, Bautista MC, Jiang SF, et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016;111:1104–13.CrossRefGoogle Scholar
  34. 34.
    Reddy KM, Chang JI, Shi JM, et al. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US Integrated Health Care System. Clin Gastroenterol Hepatol. 2016;14:1420–5.CrossRefGoogle Scholar
  35. 35.
    Ferlay JSI, Soerjomatarm I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide; IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.Google Scholar
  36. 36.
    Tsugane S, Akabane M, Inami T, et al. Urinary salt excretion and stomach cancer mortality among four Japanese populations. Cancer Causes Control. 1991;2:165–8.CrossRefGoogle Scholar
  37. 37.
    Kamada T, Haruma K, Ito M, et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 2015;20:192–8.CrossRefGoogle Scholar
  38. 38.
    Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113–24.CrossRefGoogle Scholar
  39. 39.
    Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents, Vol. IX. IARC Sci Publ. 2007;160:1–837.Google Scholar
  40. 40.
    Forman D, Bray F, Brewster DH, et al. Cancer incidence in five continents, Vol. X. IARC Sci Publ. 2014;164:1–1365.Google Scholar
  41. 41.
    Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, Vol. VIII. IARC Sci Publ. 2002;155:1–781.Google Scholar
  42. 42.
    Lee YC, Chiang TH, Liou JM, et al. Mass Eradication of Helicobacter pylori to prevent gastric cancer: theoretical and practical considerations. Gut Liver. 2016;10:12–26.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Mimi C. Tan
    • 1
  • Maya Balakrishnan
    • 1
  • David Y. Graham
    • 1
    Email author
  1. 1.Department of MedicineMichael E. DeBakey VA Medical Center and Baylor College of MedicineHoustonUSA

Personalised recommendations